Research programme: NFE2 related factor 2 and NF kappa B pathway modulators - Catabasis Pharmaceuticals

Drug Profile

Research programme: NFE2 related factor 2 and NF kappa B pathway modulators - Catabasis Pharmaceuticals

Alternative Names: CAT 4000; CAT-4001; Docosahexaenoic acid-monomethyl fumarate conjugate - Catabasis Pharmaceuticals

Latest Information Update: 17 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Catabasis Pharmaceuticals
  • Class Docosahexaenoic acids; Fumarates; Omega 3 fatty acids; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Friedreich's ataxia; Kidney disorders; Multiple sclerosis; Psoriasis

Most Recent Events

  • 17 Aug 2016 Research programme is still in preclinical development for Psoriasis, Multiple-sclerosis and Kidney-disorders in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Kidney-disorders in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top